RespireRx Pharmaceuticals Inc (CE) (RSPI) Quote

We 6 on BOB! Eyes are gearing towards us

Let's see if newes letter drops at 8 lol

Who knows but the volume is still very very small. If you are retail, I think you have to find an account in Canada, otherwise it is likely brokers or certain "sophisticated" investors scooping up scraps or settling out positions.

Hopefully we will get more detail in some update or PR, but the reality is simple. The amapkine platform is heading into a key clinical trial and the gabakine candidate has a superior preclinical profile heading towards human trials. Timing of such trials is an unknown. As the company works to collect institutional investment, lock in partnerships or deals (all of which they have been stating for years and prepping their assets for)... AND as they logically are hopefully making moves to get off the EM, I think investors are catching on and looking for options to be a part of these assets heading into clinicals.

Even if they had to double the OS shares to account for all conversions, warrants, debt, etc. That would only be a 4 million market cap today! Peanuts. Pharma's with this level of assets can easily trade 10-50x this level while clinicals are ongoing and with any clinical success unlocking significantly more value. But my position is long, so maybe a different perspective than many speculative investors.

Will do , maybe that was some of the issues they are addressing, maybe it was issues with grants and funding , who knows at this point. Dont want to guess hopefully it all comes together in the S/L GLTA

"Yes, SEC-registered companies (public companies) are required to have a majority of independent (outside) directors on their boards."
Not so. That's an exchange requirement (NYSE, AMEX, NASDAQ), not a public/SEC registered company requirement. RSPI is an SEC registered public company and it hasn't had a majority of independent Directors in some time, if ever.

Obviously it isn't just the website that needs updating. The answer to my question should have been in the latest 10-K had they filed it.
Maybe if Jeff tells you more about the board meeting after it occurs you could ask him who is on the Board. Or, in case he's reading this board, maybe he can just tell you.

Yes strange that others have been named , but not on website but as others have stated an updated webpage is needed. I think they are adding outside members for SEC rules
Yes, SEC-registered companies (public companies) are required to have a majority of independent (outside) directors on their boards. This is a key aspect of corporate governance and is mandated by stock exchange rules like those of the New York Stock Exchange and Nasdaq.
Further Clarification:
Independent Directors:
These are board members who are not employees, officers, or otherwise materially affiliated with the company. They are meant to provide an unbiased perspective and protect the interests of shareholders.
SEC Requirements:
While not explicitly stated in the SEC's regulations, the stock exchange listing requirements, which SEC-registered companies must adhere to, mandate a majority of independent directors.
Importance of Independence:
Independent directors are crucial for maintaining good corporate governance, preventing conflicts of interest, and ensuring that the board can make objective decisions in the best interests of the company and its shareholders.
Examples:
Both the New York Stock Exchange and Nasdaq require a majority of independent directors on their listed companies' boards.
Key Committees:
Independent directors are also often required to make up the majority of crucial board committees, such as the audit committee and compensation committee.
In essence, while a company can have inside directors (employees or executives), the majority of the board must be comprised of outside, independent individuals to ensure a strong corporate governance structure.

Thanks. I had seen that and it's one of the reasons I asked. It differs from other sources:

Board of Directors
Arnold S. Lippa Chairman, CSO, Interim CEO
Kathryn MacFarlane
Jeff E. Margolis
https://www.otcmarkets.com/stock/RSPI/profile

"As discussed in more detail below, on January 18, 2024, the Board of Directors (the “Board”) of RespireRx Pharmaceuticals Inc. (the “Company”) appointed a new director, Dariusz Nasiek to the Board who is considered to be an outside director."
https://www.sec.gov/ix?doc=/Archives/edgar/data/849636/000149315224003131/form8-k.htm

"Joseph Siegelbaum 75 2023 Director of the Company and retired partner of the law firm, Goodwin Procter LLP"
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000849636/000149315223012542/form10-k.htm

I got the same email a month ago when I said as we sit in EM are progress in research or clinical achievement still advancing

https://respirerx.com/board-of-directors/ here is what is on the site showing BOD ,

I am just glad he is able and willing to tell us what he can when he is asked. I might have to send him a gift card for plucking his nerves . It was a great answer so we can put that topic on the shelf. a crazy day here , strange volume for the EM hahahha

Appreciate your honorary investor relations efforts! lol

Over a million share bought while on expert market
Impressive

Is this Canada buying?

No. Development has not stopped. More in the shareholder letter. the reply

I was thinking that as well. Fingers crossed, I cant see this was disconitued and they are out trying to raise capital for that division next week

If anything possibly the analog, or the backup compound..

D5-KRM-ll-81 is the one that is no longer needed as the lead KRM-ll-81 is completing IND enabling studies and ready to go!

Correct I dont trust AI it is only as good as the info it was given to learn from , always try to find other proof once it generates an answer that is why I found the other posting. It could be like you are saying , maybe the testing they did is completed enough and they have the results needed and that is why it has been discountinued who knows. Could be cost to go forward, bring on the S/L with all the news we all are waiting on. GLTA

I think there has been plenty of publications as well as continued commentary and even on the Feb 2025 summary of Endeavourrx about KRM-ll-81 and how successful preclinicals have been and it is heading towards clinical evaluation.

AI and some of these web search systems are still "experimental" and dont always piece together info correctly. But you are correct, we all are awaiting to hear updates on all 3 platforms!

I attached two different KRM-11-81 , on by RSPI AND then the college that was doing its own , Waiting to hear from Jeff I asked him if it was true will it be addressed in the S/L and gave him the sources I sighted in last post. If anything it might be the cost to countinue without major funding to produce ect.. we shall see

In using Perplexity AI, it reports that KRM-II-81 has not yet advanced to human clinical trials but is progressing through IND-enabling studies and preclinical evaluations. Recent developments include:

1. Epilepsy Research: It suppressed epileptiform activity in brain tissue from treatment-resistant epileptic patients, with promising translational potential for clinical use.
2. Pain Management: It has shown significant efficacy in preclinical pain models, including neuropathic and acute pain, without sedation, tolerance, or dependence. It is currently being evaluated within the NIH HEAL initiative for further preclinical validation.

These results suggest that KRM-II-81 us advancing toward clinical trials but has not yet reached that stage.

Hopefully the news letter will say what is going on

Yeah I think saw there was some publications about D5-KRM-ll-81 which I believe RSPI did some work to develop backup and alternative compounds to potentially utilize in clinical efforts if needed.

This what I found ..https://synapse.patsnap.com/drug/f3e7411926d346ac958c6497d98909c6

https://synapse.patsnap.com/drug/01fc08269e8a4d51a28e39202228201a

AI Overview
Learn more
Yes, development of KRM-II-81, a drug targeting GABAA receptors (specifically alpha-2 and alpha-3 subunits), was discontinued. It was initially developed at the University of Wisconsin-Milwaukee.
KRM-II-81 - Drug Targets, Indications, Patents - Synapse
KRM-II-81: a GABRA2 agonists, GABRA3 agonists Drug, Initially developed by University of Wisconsin-Milwaukee, Now, its global high...

Patsnap Synapse
Generative AI is experimental.



Export

Any evidence that KRM-II-81 development was discontinued globally as of December 2024? Research on Perplexity A.I. stated such.

Thank you. I called them before but no luck. Guess, I will have to wait till it comes off EM.

nice to know !!!!

I was under the impression that you could phone in with TD and they would take it. Have done it myself a few times with other "experts". That said I also actually use RBC as I can enter as I please with them; no need to talk to anyone. No bid ask though so you just have to make limit buys price wise.

look up interactive brokers they may let u buy in the USA no other broker lets u buy in the USA that I know of good luck...

Lucky you can , I would love to get another 5m GLTA

Which broker do you use to buy. I called my TD Web broker to buy but they are not able to process my order.

It is commendable...

That the science/leadership team has been very patient in positioning both the ampakine and gabakine platforms on the cusp of clinical trials using very minimal investment dollars, instead utilizing government entities to fund some of these efforts.

This forum would like to see a change in effort in communication and presentation for certain, but one thing I keep thinking about is imagine what additional efforts, additional medical indications this team can spread its tentacles into IF they had a nice level of support financing that could bring in some additional talent and provide that flexibility.

Didnt ask about Board members , it was Jeff who told me

If one just google's what are preclinical drug candidates worth?

You find a wide range of opinions from 10's of million to up to 100 million. We don't have a feel for how difficult it will be to achieve targets in humans vs. animals, but that risk is with any drug. What we do know is that the preclinical profile of KRM-ll-81 appears superior to standard of care and the company has been saying it has shown success in every model of pain and epilepsy within NIH robust trials to boot. I do not think that can be understated.

There must be an inclination or a reason for why management and insiders have chosen to align with equity positions and the preferred shares need huge payment events of 15-20 million to payout a single dime! IMO, big things are on the horizon.

Can you see the bid and ask on the Canadian market?

Very smart! I wish I could do the same. My bet is that your investment today will be multiple fold before the year end.

All it will take to get this one going is one license agreement for several million dollars. Multiple license agreements are very possible as well as partnerships. That 10 million market cap will be peanuts. KRM-II-81 advancement is very promising. Just think, a pain killer with side effects and non-addictive. Big Pharma should be all over it will millions and millions. With only 950 million shares and millions of dollars coming in, the PPS value is sky high.

I continue to accumulate.

One thing to consider. I believe they valued just the OSA program alone around 20 million and a comment was made that supposedly the independent evaluation had a higher valuation than that. Now the OSA program has been silent, so maybe it is worth nothing now? Hope to hear more in the update.

But more importantly CX-1739 and KRM-ll-81. All the preclinical efforts, studies and costs paid for by RSPI or NIH or whomever are worth many millions each for certain. Couple that with signficant target markets for medical indications like ADHD, epilepsy and pain well that adds value. Having the government fund next phase of clinical trials for these candidates is also worth many millions each.. So each drug alone can easily be worth 10's of millions at this juncture and honestly I want to hear more about KRM-ll-81 and how successful preclinicals were or are currently ongoing? This is one of the unique candidates that can be worth a boatload now prior to any human clinical trials with all the NIH preclincal success.

1 penny is only a 10 million market cap today.......

Second half of this year is a good prediction of who, what and when the new direction will be. In the meantime, moving off the expert market will establish a more realistic PPS. Anxiously waiting for the press release to get a better look at the whole picture.

Exactly. Maybe the company will clear up many of the speculative ideas, however we all know what seems to be most logical course of action after having success with positioning their candidates heading into clinicals and all the executive commentary about wanting to unlock true value in the assets and of course how excited they are to see the ampakine and gabakine programs gain signficant traction. Who knows what is going on with the OSA program

We have to assume some type of negotiation was taking place in the background based upon the significance of the progress in 1 or more assets. The EM likely was a bridge to allow some time to pass without high expectations and of course the progress to continue to advance. Very plausible that we can see a slow accumulation of shares while on the EM and by the time this is ready to launch into the limelight with signficant deals in place, the baseline for the stock can be much much higher like it deserves.

I am going to speculate by 2nd half of this year this will be a transformed company with institutional support and of course much much higher valuation that will provide the flexibility to capitalize on their clinical efforts. IMO.

I am not sure what a "fair price" would be. There are many examples of companies with promising medical discoveries moving up in PPS very rapidly. If we have significant news there will be a pent-up demand for shares of RSPI. It is anyone's guess as to high it goes and how fast it will move up. If it was currently available to buy, I believe it would be approaching a penny if not higher. I wish you well as you do your DD and potential to buy in. I was fortunate to discover RSPI last July and began purchasing shares and have accumulated a few million shares and wish I had purchased much more.

speculative and subjective...

What do people consider "good" in drug development? Landing a DOD phase 2 funding deal? Passing all kinds of robust IND enabling preclinicals for high profile indications such as epilepsy and pain? Personally, I think the progress is great in terms of their platforms being in great position heading into clinicals. This whole trip to the EM with lack of communication and presentation, eh not so good. But hopefully that is beginning to change.

What is a "fair" price? Hard to say. Phase 2 funding and a premier preclinical candidate easily can be worth 10's of million if not closer to 100 million depending on the confidence and robustness of the science leading up to it. However, what is fully diluted here? 1.5 B, 2.0 B, more?

So if things go "good" and become more positive. When it becomes buyable thru the major brokerages,Will it be too late to buy at a "fair " price?

With expected news and action today on the Expert Market I would not be surprised if Jeff has been working on the compliance issues to upgrade RSPI to the OTC. If so, we could be trading in much less time than 30-60 days. Of course, we may be looking at a different market with a license agreement, partnership and/or contract to purchase one or more of RSPI discoveries. The result of any is MUCH HIGHER PPS.

RSPI can exit the Expert Market and return to public trading by meeting specific regulatory requirements.

1. Provide Current Public Information complying with SEC Rule 15c2-11.
2. Find a Market Maker that will file a new Form 211 with FINRA.
3. SEC Compliance when they become SEC registrant and resolve any issues related to missed or incomplete filings.

Once these steps are completed, the company can apply to relist on an OTC Market tier, such as OTC Pink. This process, if expedited can take as little as 30-60 days.

Yep may be some serious chasing with updates.

I get the feeling that Canadians are waiting on the bid to take whatever someone will sell. If I was able to buy, I would move my bid up and take whatever I could get. If this news is as substantial as I think it will be .0025 will be destroyed in seconds.

"BOD meeting today to review the newsletter."
Any chance you asked whoever told you that (who was that, btw?) who is on the BOD and will they ALL be at that meeting?

Yeah back at 001 rn tho small sell lmao

. 0025 HOD so far

At 0016